XENE Xenon Pharmaceuticals Inc.
$58.65▼ -0.26%
Healthcare
Other
After hours
$58.65▲ +0.00%
Sep 11, 7:30 PM ET
Volume 466.8K
Avg Volume (10D) 581.1K
Key Metrics & Fundamentals
Market Cap
$5.68B
P/E Ratio
–
Div Yield
–%
52W Range
35.60 - 72.66
% vs 50 MA
-7.56%
% vs 200 MA
10.34%
RSI-14
38.4
MACD Histogram
-0.2000
Beta (1Y vs SPY)
0.85
Free Cash Flow
-$95.67M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$122.29M
COGS
–
Operating Exp
$123.16M
Operating Income
-$123.16M
EBIT
-$123.16M
Pretax Income
-$111.32M
Net Income
-$110.74M
EPS (Diluted)
-1.11
Price & Volume History
Loading chart…
Recent News
Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback
Investor's Business Daily · Sep 10, 2026 8:17 PM
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
Barrons.com · Sep 10, 2026 6:14 PM
Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care
Insider Monkey · Sep 4, 2026 7:06 PM
Xenon to Present at Wells Fargo Healthcare Conference
GlobeNewswire · Sep 3, 2026 8:01 PM
BIOTECanada Announces 2026 Gold Leaf Award Winners, Recognizing Excellence Across Canada’s Biotechnology Ecosystem
Business Wire · Aug 31, 2026 2:49 PM
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Aug 28, 2026 8:01 PM
What Xenon Pharmaceuticals (XENE)'s New Azetukalner Phase 3 Epilepsy Data Means For Shareholders
Simply Wall St. · Aug 28, 2026 8:20 AM
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
GlobeNewswire · Aug 26, 2026 8:01 PM
Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 13, 2026 9:58 PM
Xenon Pharmaceuticals Insider Sold Shares Worth $640,550, According to a Recent SEC Filing
MT Newswires · Aug 13, 2026 8:38 PM
Financial Overview - Income Statement
Quarterly
Mar 2025
See XENE's money flow as a full page
Social Sentiment
Avg -0.30 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.